AbbVie Inc. (ABBV) Stock: Phase 3 Lymphoma Trial Cuts Progression Risk 51%

TLDR

Table of Contents

AbbVie Phase 3 lymphoma trial cuts progression or death risk by 51% in DLBCL
Epcoritamab plus R-CHOP delivers a major Phase 3 win in frontline lymphoma care
AbbVie gains fresh lymphoma data as EPCORE DLBCL-2 meets its primary endpoint
Phase 3 results strengthen AbbVie’s bispecific strategy in frontline DLBCL care
AbbVie and Genmab plan regulatory talks after positive lymphoma trial results

AbbVie reported positive Phase 3 lymphoma trial results after its shares closed 1.12% higher at $265.76. The EPCORE DLBCL-2 study showed a 51% reduction in disease progression or death risk. The findings could strengthen AbbVie’s position in frontline treatment for diffuse large B-cell lymphoma.

AbbVie Inc., ABBV

AbbVie Phase 3 Trial Meets Key Lymphoma Goal

AbbVie and Genmab tested epcoritamab with standard R-CHOP therapy in newly diagnosed DLBCL patients. The trial enrolled patients with International Prognostic Index scores ranging from two to five. Researchers compared the combination directly with R-CHOP treatment alone.

The study met its progression-free survival goal with statistically significant and clinically meaningful results. Epcoritamab plus R-CHOP reduced progression or death risk by 51% compared with standard therapy. The trial reported a hazard ratio of 0.49 and a p-value below 0.0001.

The companies also reported a generally manageable safety profile for the combination treatment. Researchers found the safety findings consistent with earlier results from epcoritamab and R-CHOP separately. AbbVie therefore gained stronger Phase 3 evidence supporting epcoritamab in earlier lymphoma treatment.

Epcoritamab Could Expand AbbVie’s Frontline Lymphoma Strategy

DLBCL represents an aggressive form of non-Hodgkin lymphoma and often requires immediate treatment. R-CHOP has remained a core frontline therapy for many patients for more than two decades. However, some patients still experience disease progression or relapse after initial treatment.

Epcoritamab uses a bispecific antibody approach that engages T cells against cancer cells. AbbVie and Genmab designed the treatment to target CD3 on T cells and CD20 on B cells. The approach aims to increase immune activity against malignant B cells.

The latest results could expand epcoritamab beyond later treatment settings if regulators approve the combination. AbbVie already sees bispecific antibodies as an important part of its hematology development strategy. The Phase 3 outcome gives the company additional clinical data supporting that strategy.

AbbVie and Genmab Prepare Regulatory Discussions

AbbVie and Genmab plan to present detailed EPCORE DLBCL-2 results at a future medical meeting. The companies will also discuss the findings with regulatory authorities across major global markets. Those talks will help determine the next development and filing steps.

The combination remains investigational and currently lacks regulatory approval for newly diagnosed DLBCL patients. Regulators will assess the complete efficacy and safety data before making any authorization decision. AbbVie must therefore complete further regulatory work before commercial use in this setting.

Epcoritamab forms part of a broader AbbVie and Genmab collaboration in blood cancer treatment. Both companies have continued studying the medicine across several lymphoma settings and treatment stages. The latest Phase 3 result adds frontline DLBCL to that growing clinical development program.

✨ Limited Time Offer